CortesJE, KimDW, Pinilla-IbarzJ, le CoutreP, PaquetteR, ChuahC, NicoliniFE, ApperleyJF, KhouryHJ, TalpazM, DiPersioJ, DeAngeloDJ, AbruzzeseE, ReaD, BaccaraniM, MüllerMC, Gambacorti-PasseriniC, WongS, LustgartenS, RiveraVM, ClacksonT, TurnerCD, HaluskaFG, GuilhotF, DeiningerMW, HochhausA, HughesT, GoldmanJM, ShahNP, KantarjianH; PACE Investigators. 2013. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369:1783–1789.
2.
DesaiJ, YassaL, MarquseeE, GeorgeS, FratesMC, ChenMH, MorganJA, DychterSS, LarsenPR, DemetriGD, AlexanderEL. 2006. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med, 145:660–664.
3.
WolterP, StefanC, DecallonneB, DumezH, BexM, CarmelietP, SchöffskiP. 2008. The clinical implications of sunitinib induced hypothyroidism: a prospective evaluation. Br J Cancer, 99:448–454.
4.
WolterP, StefanC, DecallonneB, DumezH, FieuwsS, WildiersH, ClementP, DebaereD, Van OosteromA, SchöffskiP. 2008. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell cancer. J Clin Oncol, 26:5126a.
5.
KambaT, McDonaldDM. 2007. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer, 96:1788–1795.
6.
MakitaN, IiriT. 2013. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid, 23:151–159.
